We report a case ofrhabdomyosarcoma ofthe middle ear and mastoid in a S-y ear-old boy. The patient was treated according to Int ergroup Rhabdomyosarcoma Study IV protocol (chemo-andradioth erapy), andhe expe rienced a complete remission. However; 7months after the completion oftreatment, he expe rienced a recurrence at theprimary site that spread to the brain. Despite treatm ent, the patient died ofprogressive metastasis to the lung 4 months later:
that the newer agents etoposide, ifosfamide, and melphalan have been added to the standard treatment with vincristine, actinomycin 0 , and cyclophosphamide. With respect to the radiotherapeutic component of treatment, the amount of radiation delivered to the head and neck is usually limited to 4,000 to 4,500 Gy. Salvage therapy for patients with recurrent rhabdomyosarcoma remains problematic.
Pediatric rhabdomyosarcomas that arise in the temporal bone are generally considered to be aggressive neopl asms by virtue oftheir proximity to vital structures, theirtendency to spread intracranially, and their potential for meningeal involvement. t ln this article, we describe acase ofpediatric rhabdomyosarcoma of the middle ear and mastoid that ultimately proved to be fatal.
Case report
A 3-year-old boy was referred to our clinic with 2-month history ofright -sided otalgia and bleeding from the external auditory canal. Physical examination revealed that a fleshy polypoid mass had occupied the entire external auditory canal. No cranial nerve involvement was noted, and there was no evidence of cervical lymphadenopathy.
The ear was examined under general anesthesia, and a biopsy sample was obtained. The size of the mass prevented visualization of anatomic landmarks and middle ear structures. The histopathologic features of the biopsy specimen were consistent with an embryonal rhabdomyosarcoma (figure I). Cell sta ining was positive for desmin and negative for alpha-smooth-muscle actin.
Computed tomography (CT) of the temporal bone and the brain confirmed that the mass had occupied the middle ear and mastoid ; some bone destruction was evident (figure 2). The tumo r also involved the squama of the temporal bone, the zygomatic process, and the gre ater wing of the sphenoid bone. Only minimal intracranial extension just anterior to the petrous temporal bone was seen. Th e chest x-ray was clear. A bone scan revealed isotope upt ake in the right temporal bone but no evidence of metastatic disease. The disease was classified as IRS stage III -A. 9 The patient was started on radiotherapy (4 ,500 Gy) and chemotherapy with vincristine, act inomyci n D, cyclophosphamide , etoposide, ifosfamide, and melphalan , in accordance with the IRS IV protocol. Four weeks after the completion of radio -and chemotherapy, magnetic resonance imagi ng (MRI) ofthe brain detected no evidence of residual disease. CT of the temporal bone and brain confirmed the complete resolution of the tumor. A repeat chest x-ray was clear. Seven mont hs later, the chi ld returned with right-sided fac ial palsy and headache. MRI of the brain detected a recurrence ofthe tum or in the right cerebe llopontine angle ( figure 3 ) and in the lung. The paren ts refused furth er chemotherapy, and the child died 4 month s later.
Discussion
Num erous clinical studies of rhab domyosarcomas have been comp leted as a resu lt of the efforts oflarge numb ers of cooperating gro ups, including the IRS investigators, who have pooled their patient data and resources . Rhabdomyosarcomas exhibit a bimodal pattern ofage distr ibution; their incidence peaks between the ages of 2 and 5 years and spikes again in late adolescence." Overall, 63% of all cases occur in patients younger than 10 years ."
Horn and Enterline devised a system of classifying rhabdom yosarcomas according to their histologic features ; the four types are embryonal (the most common rhabdomyosarcoma ofthe head and neck) ,pleomOlphic,alveolar, and botryoid," Affected patients often exhibi t more than one type. The alveo lar type has consis tent ly been marked by a trans location of chromosomes (2; 13) (q35qI4); in the embryonal type , the maternal allele is lost."
The clinical presentation of rhab domyosa rcoma of the midd le ear and mastoid is similar to that of chron ic suppurative otitis med ia; presentin g signs includ e purul ent 782 Figure 2 . At the initial presentation, CT through the temporal bone shows the tumor involvement of the right middle ear and mastoid and the erosion ofthe petrous bone and mastoid.
and occasionally blood -stai ned discharge, aura l polyps, and granulation tissue. As a result, the consequences of misdi agnos is can be serious if a patient with rhabdomyosarcoma is bei ng treated with antibiotics. The most common neurologic feature of rhabdomyosarcoma is facial nerve involvement. Tissue biopsy analysis is the key to diagnosis, and it sho uld be performed as soo n as poss ible. Immunohistochemical analysis with desmin is spec ific and sensitive for rhabdomyosarcoma. Recently, the demonstration of fetal hemoglobin in tumor tiss ue by immu nope roxidase stai ning has been show n to be reliably acc urate in identifying rhabdomyosa rco ma." ABBAS, AWAN sites usually behave more agg ressively than do tumors at othe r sites in the head and neck , prim ar ily becau se of their proximity to the menin ges and brain . Patients with rhabd omyosarcoma of the middle ea r and mastoi d have a particu larly poor pro gnosis . The difference in surviva l is directly related to the higher incidence of intrac ranial extension in patients with middle ear or mastoid tumors. Th e fina l results of the IRS IV trial, which has been in progress since 1991,9 have yet to be compiled.
Th e basic goa l of therapy for rhabdomyosarcoma (as it is for most so lid tum ors) is locoregional control, and preve ntion or treatm ent ofsyste mic metastasis. Therefore, all patients are treated systemically with chemotherapy and locally and reg ionally with radiotherapy, surgery, or both . Occult nodal metastasis is uncommon , and proph ylactic neck dissection is not warranted. Surgical exc ision is not always possibl e, especially in difficul t-to-reach anato mic areas or when the tumor involves intracranial structures.
The role of bone marrow transplant in patients with unfavorable tum or characteristics has been the subject of rece nt interest. The co ncept of using bon e marrow rescue in this patient population is based on the fact that the very high doses of chemotherapy used in bone marrow transplantation s may be ab le to eradicate residu al disease. By infusin g patie nts with their own stem ce lls before rescuing their bone marrow, we may be able to prevent the bone marrow toxicity that has tradit ionally limited the dosag e of chemot hera peutic age nts. Studies are under way.
